AEMD — Aethlon Medical, Inc.
Is AEMD overbought or oversold? Here is the current MarketMoodz read.
Aethlon Medical, Inc. (AEMD) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $5.01. The rating moved from Overbought to Oversold on November 14, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$5.01
- Last changeMoved from Overbought to Oversold on November 14, 2026
- SectorHealthcare
- IndustryMedical Devices
See all oversold Healthcare stocks →
AI analysis
Aethlon Medical, Inc. (AEMD) is an early-stage medical/therapeutic developer with a platform that could see meaningful upside if clinical data or partnership deals materialize; however, the company shows characteristics common to microcap biotechs — limited commercial revenue, reliance on external financing, and elevated execution risk. Current market preferences for large-cap, defensive healthcare names and sector dilution pressures temper near-term investor appetite. The outlook is binary: positive clinical/partnering news could drive sharp appreciation, while financing needs, regulatory setbacks, or weak commercialization prospects would likely produce material downside.
Key factors
- Early-stage therapeutic/medical device platform with potential applicability across viral removal and exosome-targeting applications, which could drive outsized upside if clinical/program milestones are achieved.
- Limited or uneven commercial revenue history typical of microcap biomedical firms; current operations likely dependent on external financing, partnerships or milestone/licensing payments.
- Potential near-term catalysts include clinical data readouts, partner announcements or licensing deals that could re-rate the equity if positive.
- Market structure and sentiment favor large-cap pharma and defensive healthcare names, which reduces institutional interest in smaller, higher-volatility biotechs.
- Sector-level dynamics (convertible-debt and dilution pressure in mid/small-cap biotech) increase the probability of financing-driven shareholder dilution.
- Low float/liquidity profile increases share-price volatility and can amplify moves around news or trading interest.
Risks
- Significant financing and dilution risk if cash runway is limited; issuance of equity or convertible debt could depress per-share value.
- Clinical or regulatory setbacks in core programs would materially reduce the company’s value proposition.
- Limited commercial traction and uncertain reimbursement pathways for device/therapy applications may slow revenue generation.
- Competitive pressure from larger device and biopharma firms with deeper pockets and faster commercialization capabilities.
- Low trading liquidity and retail-driven volatility can produce sharp short-term price moves independent of fundamentals.
- Macro/sector rotation away from small-cap biotech into large-cap pharma or defensive healthcare could limit rerating opportunities.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for AEMD — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.